REG4RaniGeorgeRani E. George, Ph.D.42.33789600000000-71.1072493000000068383George, RaniE.617/632-5281Professor of Pediatricscatalyst:advisorInMentoringCompletedStudentProjectcompleted student projectscatalyst:eCommonsLogineCommons LoginMentoring - Completed Student Projectprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:overviewoverviewvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofvivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson20589651George RE, Lahti JM, Adamson PC, Zhu K, Finkelstein D, Ingle AM, Reid JM, Krailo M, Neuberg D, Blaney SM, Diller LPediatric blood & cancerPhase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Oct; 55(4):629-38.Pediatr Blood Cancer2010-10-01T00:00:002010Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.Authorship 10589831029660984Powell CE, Gao Y, Tan L, Donovan KA, Nowak RP, Loehr A, Bahcall M, Fischer ES, Jänne PA, George RE, Gray NSJournal of medicinal chemistryChemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). J Med Chem. 2018 05 10; 61(9):4249-4255.J Med Chem2018-04-24T00:00:002018Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).16499899Stewart RA, Arduini BL, Berghmans S, George RE, Kanki JP, Henion PD, Look ATDevelopmental biologyZebrafish foxd3 is selectively required for neural crest specification, migration and survival. Dev Biol. 2006 Apr 01; 292(1):174-88.Dev Biol2006-02-23T00:00:002006Zebrafish foxd3 is selectively required for neural crest specification, migration and survival.22789543Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RECancer cellThe ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 2012 Jul 10; 22(1):117-30.Cancer Cell2012-07-10T00:00:002012The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.18056449Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, Thorner PS, Smith KM, Look AT, Yeger H, Miller FD, Irwin MS, Thiele CJ, Kaplan DRCancer researchNeuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res. 2007 Dec 01; 67(23):11234-43.Cancer Res2007-12-01T00:00:002007Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell.18923525George RE, Sanda T, Hanna M, Fröhling S, Luther W, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look ATNatureActivating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16; 455(7215):975-8.Nature2008-10-16T00:00:002008Activating mutations in ALK provide a therapeutic target in neuroblastoma.19435921Volchenboum SL, Li C, Li S, Attiyeh EF, Reynolds CP, Maris JM, Look AT, George RECancer researchComparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res. 2009 May 15; 69(10):4143-9.Cancer Res2009-05-12T00:00:002009Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis.30232453Choe J, Lin S, Zhang W, Liu Q, Wang L, Ramirez-Moya J, Du P, Kim W, Tang S, Sliz P, Santisteban P, George RE, Richards WG, Wong KK, Locker N, Slack FJ, Gregory RINaturemRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature. 2018 09; 561(7724):556-560.Nature2018-09-19T00:00:002018mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis.Authorship 10935771221945349Azarova AM, Gautam G, George RESeminars in cancer biologyEmerging importance of ALK in neuroblastoma. Semin Cancer Biol. 2011 Oct; 21(4):267-75.Semin Cancer Biol2011-09-16T00:00:002011Emerging importance of ALK in neuroblastoma.D020794Chemicals & Drugs63116590.555179Receptor Protein-Tyrosine KinasesD018663Chemicals & Drugs53700.951813Adrenergic AgentsAuthorship 11470112030988284Krajewska M, Dries R, Grassetti AV, Dust S, Gao Y, Huang H, Sharma B, Day DS, Kwiatkowski N, Pomaville M, Dodd O, Chipumuro E, Zhang T, Greenleaf AL, Yuan GC, Gray NS, Young RA, Geyer M, Gerber SA, George RENature communicationsCDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat Commun. 2019 04 15; 10(1):1757.Nat Commun2019-04-15T00:00:002019CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation.D009447Disorders45812140.548661NeuroblastomaD018844Chemicals & Drugs3446700.744356Cyclin-Dependent KinasesD010655Chemicals & Drugs79900.930166PhenylenediaminesMedicinePathologyPediatricsRadiation OncologyHematology/OncologyBrigham and Women's HospitalBoston Children's HospitalDana-Farber Cancer InstituteMassachusetts General HospitalWBL3WendyLondonWendy B London, Ph.D.97428London, WendyProfessor of PediatricsLRD2LisaDillerLisa Robin Diller, M.D.42.33789600000000-71.1072493000000066744Diller, LisaProfessor of PediatricsARP4AntonioPerez-AtaydeAntonio Rafael Perez-Atayde, M.D.42.33743600000000-71.1054470000000047667Perez-Atayde, AntonioProfessor of PathologyATL1A.LookA. Thomas Look, M.D.42.33789600000000-71.1072493000000057807Look, A.Professor of PediatricsLEL1LeslieLehmannLeslie Elaine Lehmann, M.D.42.33789600000000-71.1072493000000016529Lehmann, LeslieAssociate Professor of PediatricsSES6StephenSallanStephen Earl Sallan, M.D.42.33789600000000-71.1072493000000046338Sallan, StephenProfessor of Pediatrics1150selected publications6.149590.00212271288research areas2.011070.020558741coauthor of89.67379.5112160similar toDGN1DavidNathanDavid G. Nathan, M.D.42.33789600000000-71.1072493000000019587Nathan, DavidRobert A. Stranahan Distinguished Professor of PediatricsMAD35M AivenDyerM Aiven Dyer, M.D.58516Dyer, M AivenInstructor in Radiation OncologyAPT1AliceShawAlice Tsang Shaw, M.D., Ph.D.42.36241700000000-71.068937000000007296Shaw, AliceProfessor of MedicineALF1A.FrazierA. Lindsay Frazier, M.D.42.33789600000000-71.1072493000000014157Frazier, A.Professor of PediatricsMG171MariellaFilbinMariella Gruber Filbin, M.D.,Ph.D.42.33789600000000-71.1072493000000074141Filbin, MariellaAssociate Professor of PediatricsAuthorship 11740863031346162Wong M, Sun Y, Xi Z, Milazzo G, Poulos RC, Bartenhagen C, Bell JL, Mayoh C, Ho N, Tee AE, Chen X, Li Y, Ciaccio R, Liu PY, Jiang CC, Lan Q, Jayatilleke N, Cheung BB, Haber M, Norris MD, Zhang XD, Marshall GM, Wang JY, Hüttelmaier S, Fischer M, Wong JWH, Xu H, Perini G, Dong Q, George RE, Liu TNature communicationsJMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. Nat Commun. 2019 07 25; 10(1):3319.Nat Commun2019-07-25T00:00:002019JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.Authorship 11794761831391581Debruyne DN, Dries R, Sengupta S, Seruggia D, Gao Y, Sharma B, Huang H, Moreau L, McLane M, Day DS, Marco E, Chen T, Gray NS, Wong KK, Orkin SH, Yuan GC, Young RA, George RENatureBORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. Nature. 2019 08; 572(7771):676-680.Nature2019-08-07T00:00:002019BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.Authorship 11913151431498151Bayles I, Krajewska M, Pontius WD, Saiakhova A, Morrow JJ, Bartels C, Lu J, Faber ZJ, Fedorov Y, Hong ES, Karnuta JM, Rubin B, Adams DJ, George RE, Scacheri PCThe Journal of clinical investigationEx vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma. J Clin Invest. 2019 10 01; 129(10):4377-4392.J Clin Invest2019-10-01T00:00:002019Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma.true1Associate Professor of PediatricsAssociate Professor of Pediatricstrue1Professor of PediatricsProfessor of Pediatricstrue1Robert A. Stranahan Distinguished Professor of PediatricsRobert A. Stranahan Distinguished Professor of Pediatricstrue1Professor of MedicineProfessor of Medicinetrue1Professor of PediatricsProfessor of PediatricsAuthorship 1223391Authorship 12110862231862972Murphy AJ, Chen X, Pinto EM, Williams JS, Clay MR, Pounds SB, Cao X, Shi L, Lin T, Neale G, Morton CL, Woolard MA, Mulder HL, Gil HJ, Rehg JE, Billups CA, Harlow ML, Dome JS, Houghton PJ, Easton J, Zhang J, George RE, Zambetti GP, Davidoff AMNature communicationsForty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor. Nat Commun. 2019 12 20; 10(1):5806.Nat Commun2019-12-20T00:00:002019Forty-five patient-derived xenografts capture the clinical and biological heterogeneity of Wilms tumor.Authorship 1381194Authorship 1166103Authorship 12274793232060267Zeineldin M, Federico S, Chen X, Fan Y, Xu B, Stewart E, Zhou X, Jeon J, Griffiths L, Nguyen R, Norrie J, Easton J, Mulder H, Yergeau D, Liu Y, Wu J, Van Ryn C, Naranjo A, Hogarty MD, Kaminski MM, Valentine M, Pruett-Miller SM, Pappo A, Zhang J, Clay MR, Bahrami A, Vogel P, Lee S, Shelat A, Sarthy JF, Meers MP, George RE, Mardis ER, Wilson RK, Henikoff S, Downing JR, Dyer MANature communicationsMYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nat Commun. 2020 02 14; 11(1):913.Nat Commun2020-02-14T00:00:002020MYCN amplification and ATRX mutations are incompatible in neuroblastoma.Authorship 1612361Authorship 1232872832142683Cohen MA, Zhang S, Sengupta S, Ma H, Bell GW, Horton B, Sharma B, George RE, Spranger S, Jaenisch RCell stem cellFormation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras. Cell Stem Cell. 2020 04 02; 26(4):579-592.e6.Cell Stem Cell2020-03-05T00:00:002020Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras.Authorship 1421951Authorship 12703822332653773Moreno L, Barone G, DuBois SG, Molenaar J, Fischer M, Schulte J, Eggert A, Schleiermacher G, Speleman F, Chesler L, Geoerger B, Hogarty MD, Irwin MS, Bird N, Blanchard GB, Buckland S, Caron H, Davis S, De Wilde B, Deubzer HE, Dolman E, Eilers M, George RE, George S, Jaroslav Š, Maris JM, Marshall L, Merchant M, Mortimer P, Owens C, Philpott A, Poon E, Shay JW, Tonelli R, Valteau-Couanet D, Vassal G, Park JR, Pearson ADJEuropean journal of cancer (Oxford, England : 1990)Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Eur J Cancer. 2020 09; 136:52-68.Eur J Cancer2020-07-09T00:00:002020Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.Authorship 13381471133685491Dries R, Zhu Q, Dong R, Eng CL, Li H, Liu K, Fu Y, Zhao T, Sarkar A, Bao F, George RE, Pierson N, Cai L, Yuan GCGenome biologyGiotto: a toolbox for integrative analysis and visualization of spatial expression data. Genome Biol. 2021 03 08; 22(1):78.Genome Biol2021-03-08T00:00:002021Giotto: a toolbox for integrative analysis and visualization of spatial expression data.true1Associate Professor of PediatricsAssociate Professor of Pediatricstrue1Instructor in Radiation OncologyInstructor in Radiation OncologyAuthorship 13759761634260934Huang H, Gont A, Kee L, Dries R, Pfeifer K, Sharma B, Debruyne DN, Harlow M, Sengupta S, Guan J, Yeung CM, Wang W, Hallberg B, Palmer RH, Irwin MS, George RECell reportsExtracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration. Cell Rep. 2021 07 13; 36(2):109363.Cell Rep2021-07-13T00:00:002021Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration.true1Professor of PediatricsProfessor of PediatricsAuthorship 14414171135198433Gao Y, Volegova M, Nasholm N, Das S, Kwiatkowski N, Abraham BJ, Zhang T, Gray NS, Gustafson C, Krajewska M, George REFrontiers in oncologySynergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Front Oncol. 2021; 11:773186.Front Oncol2022-01-27T00:00:002022Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma.Authorship 15001622936138189Sengupta S, Das S, Crespo AC, Cornel AM, Patel AG, Mahadevan NR, Campisi M, Ali AK, Sharma B, Rowe JH, Huang H, Debruyne DN, Cerda ED, Krajewska M, Dries R, Chen M, Zhang S, Soriano L, Cohen MA, Versteeg R, Jaenisch R, Spranger S, Romee R, Miller BC, Barbie DA, Nierkens S, Dyer MA, Lieberman J, George RENature cancerMesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Nat Cancer. 2022 10; 3(10):1228-1246.Nat Cancer2022-09-22T00:00:002022Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes.Authorship 15115051536521927Cornel AM, Dunnebach E, Hofman DA, Das S, Sengupta S, van den Ham F, Wienke J, Strijker JGM, van den Beemt DAMH, Essing AHW, Koopmans B, Engels SAG, Lo Presti V, Szanto CS, George RE, Molenaar JJ, van Heesch S, Dierselhuis MP, Nierkens SJournal for immunotherapy of cancerEpigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch. J Immunother Cancer. 2022 12; 10(12).J Immunother Cancer2022-12-01T00:00:002022Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.sas5973SatyakiSenguptaSatyaki Sengupta, Ph.D.211694Sengupta, SatyakiResearch Fellow in Pediatricstrue1Research Fellow in PediatricsResearch Fellow in Pediatricstrue1Associate Professor of PediatricsAssociate Professor of Pediatricstrue1Professor of PediatricsProfessor of Pediatricstrue1Professor of PediatricsProfessor of Pediatricstrue1Professor of PediatricsProfessor of Pediatricstrue1Professor of PathologyProfessor of PathologyAuthorship 6656596Authorship 66117027Authorship 651640923754957Pei D, Luther W, Wang W, Paw BH, Stewart RA, George REPLoS geneticsDistinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models. PLoS Genet. 2013 Jun; 9(6):e1003533.PLoS Genet2013-06-06T00:00:002013Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models.2013-09-02T00:00:002013-05-22T00:00:00Cleavage of the Anaplastic Lymphoma Kinase in NeuroblastomaSummerAuthorship 2672371Authorship 2624771Authorship 5550958Authorship 7653581425228590Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George REOncotargetMolecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget. 2014 Sep 30; 5(18):8737-49.Oncotarget2014-09-30T00:00:002014Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.Authorship 7713581625416950Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A, Perez-Atayde A, Wong KK, Yuan GC, Gray NS, Young RA, George RECellCDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014 Nov 20; 159(5):1126-1139.Cell2014-11-06T00:00:002014CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.Authorship 7739172325490451Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, Barbie DA, Bradner JE, George RE, Gray NS, Young RA, Wong KKCancer cellTargeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014 Dec 08; 26(6):909-922.Cancer Cell2014-12-08T00:00:002014Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.Authorship 950741Authorship 307251Authorship 2814571Authorship 4202944Authorship 22405513Authorship 4554259DFCIAuthorship 3986744Authorship 5655333SD56StevenDuBoisSteven Gary DuBois, M.D.5118DuBois, StevenAssociate Professor of PediatricsAuthorship 829872424667968Jamin Y, Glass L, Hallsworth A, George R, Koh DM, Pearson AD, Chesler L, Robinson SPPloS oneIntrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. PLoS One. 2014; 9(3):e92886.PLoS One2014-03-25T00:00:002014Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma.26105625Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, George RE, Lucas KGCancer immunology, immunotherapy : CIIA phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. 2015 Oct; 64(10):1251-60.Cancer Immunol Immunother2015-06-24T00:00:002015A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.Authorship 8354687Authorship 844747126362998George REClinical cancer research : an official journal of the American Association for Cancer ResearchSeek and Ye Shall Find: Subclonal Anaplastic Lymphoma Kinase Mutations. Clin Cancer Res. 2015 Nov 01; 21(21):4747-9.Clin Cancer Res2015-09-11T00:00:002015Seek and Ye Shall Find: Subclonal Anaplastic Lymphoma Kinase Mutations.Authorship 852325626568289Hatcher JM, Bahcall M, Choi HG, Gao Y, Sim T, George R, Jänne PA, Gray NSJournal of medicinal chemistryDiscovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. J Med Chem. 2015 Dec 10; 58(23):9296-9308.J Med Chem2015-11-25T00:00:002015Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.Authorship 8608208Authorship 858230226747894Versteeg R, George RECancer discoveryTargeting ALK: The Ten Lives of a Tumor. Cancer Discov. 2016 Jan; 6(1):20-1.Cancer Discov2016-01-01T00:00:002016Targeting ALK: The Ten Lives of a Tumor.26523776Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, van Noesel MM, George RE, Tytgat GA, Molenaar JJ, Versteeg RNature geneticsTERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet. 2015 Dec; 47(12):1411-4.Nat Genet2015-11-02T00:00:002015TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.Authorship 3081252Authorship 8897471026996379Carter DR, Sutton SK, Pajic M, Murray J, Sekyere EO, Fletcher J, Beckers A, De Preter K, Speleman F, George RE, Haber M, Norris MD, Cheung BB, Marshall GMMolecular oncologyGlutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. Mol Oncol. 2016 06; 10(6):866-78.Mol Oncol2016-03-02T00:00:002016Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.1Associate Professor6Fellow or Post Doc0Full Professor4Instructor2021-02-28GEORGE, RANI E2016-03-07Transcriptional CDKs as therapeutic targets in MYC-dependent cancersR01CA1973362009-02-28GEORGE, RANI E2004-07-20Zebrafish Peripheral Sympathetic Nervous System Development and NeuroblastomaK08NS0479832022-02-28GEORGE, RANI E2011-01-01The ALK receptor tyrosine kinase as a therapeutic target in neuroblastomaR01CA148688Principal InvestigatorPrincipal InvestigatorPrincipal InvestigatorAuthorship 9270658Authorship 2426898Authorship 958377928220815Sun M, Ha N, Pham DH, Frederick M, Sharma B, Naruse C, Asano M, Pipkin ME, George RE, Thai THScientific reportsCbx3/HP1? deficiency confers enhanced tumor-killing capacity on CD8+ T cells. Sci Rep. 2017 02 21; 7:42888.Sci Rep2017-02-21T00:00:002017Cbx3/HP1? deficiency confers enhanced tumor-killing capacity on CD8+ T cells.12960120Carlin S, Mairs RJ, McCluskey AG, Tweddle DA, Sprigg A, Estlin C, Board J, George RE, Ellershaw C, Pearson AD, Lunec J, Montaldo PG, Ponzoni M, van Eck-Smit BL, Hoefnagel CA, van den Brug MD, Tytgat GA, Caron HNClinical cancer research : an official journal of the American Association for Cancer ResearchDevelopment of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res. 2003 Aug 15; 9(9):3338-44.Clin Cancer Res2003-08-15T00:00:002003Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.15069390George RE, Lipshultz SE, Lipsitz SR, Colan SD, Diller LThe Journal of pediatricsAssociation between congenital cardiovascular malformations and neuroblastoma. J Pediatr. 2004 Apr; 144(4):444-8.J Pediatr2004-04-01T00:00:002004Association between congenital cardiovascular malformations and neuroblastoma.17327916George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortina P, Look AT, Maris JMPloS oneGenome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One. 2007 Feb 28; 2(2):e255.PLoS One2007-02-28T00:00:002007Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.16782928George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, Pulsipher M, Grupp SA, Diller LJournal of clinical oncology : official journal of the American Society of Clinical OncologyHigh-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006 Jun 20; 24(18):2891-6.J Clin Oncol2006-06-20T00:00:002006High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.17020972Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM, Diller L, Look AT, George REClinical cancer research : an official journal of the American Association for Cancer ResearchDoes MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. Clin Cancer Res. 2006 Oct 01; 12(19):5693-7.Clin Cancer Res2006-10-01T00:00:002006Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.450 Brookline AveDana-Farber Cancer InstituteDana 640E450 Brookline AveBoston02215MA21572589Deng X, Wang J, Zhang J, Sim T, Kim ND, Sasaki T, Luther W, George RE, Jänne PA, Gray NSACS medicinal chemistry lettersDiscovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. ACS Med Chem Lett. 2011 May 12; 2(5):379-384.ACS Med Chem Lett2011-03-15T00:00:002011Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors.16116152George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look ATJournal of clinical oncology : official journal of the American Society of Clinical OncologyHyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005 Sep 20; 23(27):6466-73.J Clin Oncol2005-08-22T00:00:002005Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.22589483Matthay KK, George RE, Yu ALClinical cancer research : an official journal of the American Association for Cancer ResearchPromising therapeutic targets in neuroblastoma. Clin Cancer Res. 2012 May 15; 18(10):2740-53.Clin Cancer Res2012-05-15T00:00:002012Promising therapeutic targets in neuroblastoma.Authorship 1000553228718439Sengupta S, George RETrends in cancerSuper-Enhancer-Driven Transcriptional Dependencies in Cancer. Trends Cancer. 2017 04; 3(4):269-281.Trends Cancer2017-04-12T00:00:002017Super-Enhancer-Driven Transcriptional Dependencies in Cancer.20950435Garcia I, Mayol G, Rodríguez E, Suñol M, Gershon TR, Ríos J, Cheung NK, Kieran MW, George RE, Perez-Atayde AR, Casala C, Galván P, de Torres C, Mora J, Lavarino CMolecular cancerExpression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer. 2010 Oct 15; 9:277.Mol Cancer2010-10-15T00:00:002010Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma.22162143George RE, Perez-Atayde AR, Yao X, London WB, Shamberger RC, Neuberg D, Diller LPediatric blood & cancerTumor histology during induction therapy in patients with high-risk neuroblastoma. Pediatr Blood Cancer. 2012 Sep; 59(3):506-10.Pediatr Blood Cancer2011-12-11T00:00:002011Tumor histology during induction therapy in patients with high-risk neuroblastoma.19275511Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, Cui X, Rentrop WB, Morris SWExpert review of anticancer therapyAnaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009 Mar; 9(3):331-56.Expert Rev Anticancer Ther2009-03-01T00:00:002009Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.18334619Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, Pomeroy SL, Maris JM, Look AT, Meyerson M, Peeper DS, Carter BD, Kaelin WGGenes & developmentThe kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008 Apr 01; 22(7):884-93.Genes Dev2008-03-11T00:00:002008The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor.Authorship 10353661429276047Gao Y, Zhang T, Terai H, Ficarro SB, Kwiatkowski N, Hao MF, Sharma B, Christensen CL, Chipumuro E, Wong KK, Marto JA, Hammerman PS, Gray NS, George RECell chemical biologyOvercoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. Cell Chem Biol. 2018 02 15; 25(2):135-142.e5.Cell Chem Biol2017-12-21T00:00:002017Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors.20408767George RE, Diller L, Bernstein MLExpert opinion on pharmacotherapyPharmacotherapy of neuroblastoma. Expert Opin Pharmacother. 2010 Jun; 11(9):1467-78.Expert Opin Pharmacother2010-06-01T00:00:002010Pharmacotherapy of neuroblastoma.22439933Zhu S, Lee JS, Guo F, Shin J, Perez-Atayde AR, Kutok JL, Rodig SJ, Neuberg DS, Helman D, Feng H, Stewart RA, Wang W, George RE, Kanki JP, Look ATCancer cellActivated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012 Mar 20; 21(3):362-73.Cancer Cell2012-03-20T00:00:002012Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.